glp 1 agonist benefits In patients with #obesity, incretin-based therapies such as GLP-1 receptor agonists are reported to result in mean weight reductions of approximately 15 to 20% along with additional health benefits, including decreased cardiovascular Can one drug do it

Thorpe KM, Patel C, Harrison R, Eapen Z, Ambrosy A, Coker R, Jenkins W, Anderson M, Migdalis I, Eliasson B, Chiang C, Cuadrado J, Santos NG, Litvak M, Loureyro J, Maldonado N, Gaal LV, Mihaylova-Shumkova R, Akhras R, Grondin F, Gupta M, Jones M, Lonn E, Lastuvka J, Cadinot D, Chevts J, Grosskopf J, Heymer P, Jung T, Luedemann J, Maxeiner S, Milek K, Regner S, Rieker W, Seufert J, Dimitriadis G, Pagkalos E, Mucsi J, Bonadonna R, Cosmo SE, Ponzani P, Trevisan R, Jang HC, Lee EY, Yu J, Vidrio-Velzquez M, Viergever EP, Guttormsen G, Wium C, Gadzinski W, Krzyzagorska E, Madej A, Romanczuk P, Garganeeva A, Kharakhulakh M, Lesnov V, Vasilevskaya O, Dawood S, Calonge AN, Charneco MQ, Rodrguez IR, Lundman P, Sderberg S, Chen JF, Sansanayudh N, Zlova T, Cookson T, Akhter F, Baum H, Aguiar RBD, Cheung D, Cohen A, Farris N, Forgosh L, Hartman I, Hermany P, Kulback S, Labroo A, Little R, Mehta A, Moran J, Rasouli N, Tan M, Wynne A, Yazdani S, Stewart M, Patel P, Sabol MB, Casson E, Hereghty B, Fernandez-Salazar E, Donaldson J, Jarosz M, Richards J, McLaughlin P, Breneman J, Shitut A, Bhosale A, Naicker P, Dumbre S

This idea was bolstered by a series of experiments conducted between 1890 and 1905 by Marcel Eugne mile Gley, a French physiologist

Individual Results Vary Your results with semaglutide may differ from others

Y., et al

Recent reviews note the need for careful monitoring of cardiometabolic effects, particularly since long-term safety data in adolescents are still emerging